SeraCare Life Sciences acquired Kirkegaard & Perry Laboratories (KPL), a provider of antibodies and related reagents for the diagnostic and life sciences markets. With the acquisition, SeraCare says it has expanded its portfolio of products designed to help diagnostic researchers develop in vitro diagnostic assays through both off-the-shelf products and custom antibody design.
KPL’s portfolio of products includes immunochemicals for in vitro diagnostics including primary and secondary antibodies as well as reagents and kits targeting ELISA, Western blotting, immunohistology, protein labeling, nucleic acid labeling, sample prep, protein purification, and recombinant protein detection and analysis. SeraCare—which already provides biological products and control materials for infectious disease, women’s health, and genetic testing into oncology, autoimmune, allergy, and companion diagnostics—says KPL’s products will support expansion from its core strengths.
“Our product portfolios, research and development, and manufacturing expertise are complementary and will enable us to deliver a full suite of capabilities to the diagnostics market,” said Albert Perry, KPL’s president and CEO, in a statement.
SeraCare secured funding for the acquisition and refinanced its existing debt with Madison Capital Funding and BB&T Capital Partners. Kirkland & Ellis provided legal advice to SeraCare for the transaction.